Ibrutinib Monotherapy: Frontline CLL Landmark DataThe established standard and target to improve upon in frontline CLL is single-agent BTK inhibition. Doublets and TripletsThe primary strategy to building on the single-agent BTK inhibitor gold standard has been exploring doublet and triplet regimens in the frontline CLL setting. Allan noted that the study was powered to measure AV vs chemotherapy, so that comparison was the primary end point evaluation for statistical significance. The HR for PFS for AVO vs FCR/BR (HR 0.35; 95% CI, 0.23-53) was much better than the HR for PFS for AV vs FCR/BR (HR 0.69; 95% CI, 0.48-97). The HRs for PFS were similar with AV (HR, 0.67; 95% CI, 0.39-1.14) and AVO (HR, 0.58; 95% CI, 0.32-1.02).